KLF10 and fatty liver disease: Similarly, AMPK activation in the liver reduces lipogenesis in vivo and protects against high-fructose diet-induced hepatic steatosis [62], indicating that AMPK–KLF10 axis activation could be a beneficial target for liver fibrosis treatment.